A strategy for organ allografts without using immunosuppressants or irradiation
-
- Haruo Morita
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Kikuya Sugiura
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Muneo Inaba
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Tienan Jin
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Junji Ishikawa
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Zhexiong Lian
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Yasushi Adachi
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Shinji Sogo
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Kazuya Yamanishi
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Hideo Taki
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Masakazu Adachi
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Takato Noumi
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Yasuo Kamiyama
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Robert A. Good
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
-
- Susumu Ikehara
- First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
Description
<jats:p>A strategy to achieve regular and long lasting organ and tissue allografts without using immunosuppressants and/or irradiation has been established for mice. One hundred percent of skin allografts can be induced to survive >350 days after transplantation if spleen cells from the same donors are first injected into the portal vein of the recipients. The mechanisms underlying this long-term tolerance induction can be described as follows: (<jats:italic>i</jats:italic>) donor T cells from the spleen of the donor facilitate the acceptance of the allogeneic engraftment, (<jats:italic>ii</jats:italic>) donor-specific anergy is induced in the cytotoxic T-lymphocytes of the recipients, (<jats:italic>iii</jats:italic>) T helper type 2 cells become the dominant T cells in the recipients that are accepting the skin transplants, and (<jats:italic>iv</jats:italic>) a lasting chimerism (microchimerism) is established in these recipients. This strategy, perhaps with minor modifications, might permit one also to overcome major barriers to organ allografting in humans. If this were the case, it could represent production of long lasting immunologic tolerance without need for irradiation or cytotoxic chemo-preparative regimen and as such could greatly facilitate allotransplantation free of episodes of chronic or acute rejection or toxic and damaging preparatory regimens.</jats:p>
Journal
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 95 (12), 6947-6952, 1998-06-09
Proceedings of the National Academy of Sciences
- Tweet
Details 詳細情報について
-
- CRID
- 1363388843745396992
-
- ISSN
- 10916490
- 00278424
-
- Data Source
-
- Crossref